|
Apr 24
|
Bristol-Myers Squibb (NYSE:BMY) Reports Upbeat Q1, Full-Year Outlook Slightly Exceeds Expectations
|
|
Apr 24
|
Bristol Myers: Q1 Earnings Snapshot
|
|
Apr 24
|
Bristol Myers posts higher-than-expected quarterly revenue on cancer drug sales
|
|
Apr 24
|
Bristol Myers Squibb Reports First Quarter Financial Results for 2025
|
|
Apr 23
|
These Stocks Moved the Most Today: Tesla, Intel, Enphase, Bristol Myers, Boeing, AT&T, and More
|
|
Apr 23
|
Biotech Stock Roundup: BMY Down on Study Data, Updates From REGN & More
|
|
Apr 23
|
Bristol Myers Stock Falls As Schizophrenia Trial Failure Dims Outlook
|
|
Apr 23
|
Is Bristol-Myers Squibb Company (BMY) the Best Stock That Will Always Grow?
|
|
Apr 23
|
Bristol Myers' Cobenfy Falls Short On Primary Endpoint In Phase 3 Schizophrenia Trial, Stock Slides
|
|
Apr 23
|
The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi
|
|
Apr 23
|
Bristol-Myers Squibb (BMY) Reports Earnings Tomorrow: What To Expect
|
|
Apr 23
|
BMS’ schizophrenia therapy fails in Phase III trial as an adjunctive treatment
|
|
Apr 23
|
Bristol Myers’ prized schizophrenia drug stumbles in testing
|
|
Apr 22
|
Bristol Myers Sheds 6% After Promising Schizophrenia Drug Flops In Phase 3 Test
|
|
Apr 22
|
Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia
|
|
Apr 22
|
Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term
|
|
Apr 22
|
Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?
|
|
Apr 22
|
Patent Cliff Looms Large for Bristol-Myers Squibb Stock (BMY)
|
|
Apr 19
|
Bristol Myers says FDA updates Camzyos label to simplify treatment
|
|
Apr 18
|
Bristol-Myers Squibb (NYSE:BMY) Gains FDA Approval To Simplify Camzyos Monitoring Process
|